When is a bispecific worth the complexity? Defining the evidence needed to justify a multispecific format
09 Feb 2027
Formats & Scaffolds
- When does combining two mechanisms in a single molecule actually provide an advantage over a conventional antibody or combination therapy?
- What evidence do we need to see before deciding that a multispecific format is really justified?
- How do we know whether the individual building blocks have the right potency, geometry, valency, and balance of activity to work well together?
- How early should developability, PK, manufacturing, and dosing considerations start influencing the format we choose?
- How much therapeutic benefit do we need to justify the added complexity of developing a multispecific molecule?
